Talk:Granulocyte macrophage colony-stimulating factor

From Wikipedia, the free encyclopedia

This article is within the scope of the following WikiProjects:

WikiProject Pharmacology (Rated start-Class) Granulocyte macrophage colony-stimulating factor is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome. Start This article has been rated as start-Class on the quality scale. Mid This article has been rated as mid-importance for this Project's importance scale. WikiProject Medicine (Rated start-Class) This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess. Start This page has been rated as start-Class on the quality assessment scale Mid This article has been rated as Mid-importance on the importance assessment scale Molecular and Cellular Biology WikiProject (Rated start-Class) MCB Portal This article is within the scope of the Molecular and Cellular Biology WikiProject. To participate, visit the WikiProject for more information. The WikiProject's current monthly collaboration is focused on improving Restriction enzyme. Start This article has been rated as start-Class on the assessment scale. Mid This article is on a subject of mid-importance within molecular and cellular biology. Article Grading: The article has been rated for quality and/or importance but has no comments yet. If appropriate, please review the article and then leave comments here to identify the strengths and weaknesses of the article and what work it will need.

[edit] Controversy

I don't really understand what is controversial about that part? Drug development companies always pay for trials(yeah, no one pay for them) and report results in press releases and publications. That is common practice. FDA do it job in estimating drug performance and approve or not approve particular drug for further studies and use as a treatment. TestPilot 05:32, 30 November 2006 (UTC)

I think the controversy stems from the inherent conflict of interest: the person who co-owns the patent on the drug is also the same person who is the lead author of a study saying the drug is highly effective. That is, the study he wrote, which is supposed to be objective, scientific and unbiased, would likely result in increased sales of his drug, which makes him more money. Katalaveno 18:53, 30 November 2006 (UTC)

I read this entry and looked at the source in the Phoenix. Why was the rest of the article about this study not quoted? "Korzenik says that he went to great lengths to “create a firewall” to protect the integrity of that study, which he and a colleague initiated when he was at Washington University, in St. Louis. The university established two committees to review the study results and process, and it even sent the compiled data to the outside clinicians who oversaw the bulk of the trials for individual review. Since receiving the patent, Korzenik has removed himself from further involvement in any research or promotion of the product."

Crohns----